Bryce A. Kerlin

Bryce A. Kerlin

Auto-generated profile, based on publicly available information

Bryce A. Kerlin

Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
BKBryce A. Kerlin
Bryce A. Kerlin
RARose Ayoob
Rose Ayoob
WSWilliam E. Smoyer
William E. Smoyer
Summary: After infections, thromboembolism is considered by many experts to be the most significant life-threatening complication of nephrotic syndrome. The purpose of this review is to summarize the epidemiology, clinical and molecular pathophysiology, and management of this complication. Children (2.8%) are less likely than adults (26.7%) with nephrotic syndrome to develop thromboembolism. However, infants and children aged >12 years are at much greater risk. Membranous histologic changes increase thromboembolic risk at all ages; in particular, adults with membranous nephropathy have the highest reported risk (37.0%) and children with membranous histology have a rate (25%) that approaches the overall adult rate. There are striking, but variable, pathologic alterations of molecular hemostasis associated with nephrotic syndrome. No clear molecular therapeutic targets have been identified, but most studies show that the major pathologic changes involve antithrombin, fibrinogen, and factors V and VIII. There is inadequate evidence to support routine prophylactic therapy. Therapy includes anticoagulation in all cases, with thrombolysis reserved for those with the most severe thromboembolic disease. Future hemostatic research in nephrotic syndrome should focus on identifying cohorts at highest risk for thrombosis through the use of clinical markers and biomarkers as well as searching for molecular targets to correct the prothrombotic pathophysiology of this disease.

3 November 2015 in Nano Letters
Verified
Journal Article
Closed access
BLBin Li
Bin Li
XLXiao Luo
Xiao Luo
BDBinbin Deng
Binbin Deng
JWJunfeng Wang
Junfeng Wang
DMDavid W. McComb
David W. McComb
YDYizhou Dong
Yizhou Dong

28 October 2011 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
BSBhuvana A. Setty
Bhuvana A. Setty
SOSarah H. O'Brien
Sarah H. O'Brien
BKBryce A. Kerlin
Bryce A. Kerlin

1 November 2003 in Blood
Verified
Journal Article
Closed access
PDF file
BKBryce A. Kerlin
Bryce A. Kerlin
SYS. Betty Yan
S. Betty Yan
BIBerend H. Isermann
Berend H. Isermann
JBJohn T. Brandt
John T. Brandt
RSRashmi Sood
Rashmi Sood
JDJean-Francois Dhainaut
Jean-Francois Dhainaut
Sepsis is associated with systemic inflammation, coagulopathy, and disrupted protein C (PC) pathway function. The effect of prothrombotic polymorphism, factor V Leiden (Arg506Gln; FV Leiden), was examined in a large clinical trial (PROWESS) of severe sepsis and a mouse endotoxemia model. In PROWESS, 4.1% (n = 65) of patients were heterozygous FV Leiden (VL+/–) carriers. The 28-day mortality was lower in VL+/– (13.9%) than in non-FV Leiden (VL–/–; 27.9%) patients (P = .013). The mortality benefit of recombinant human activated PC (rhAPC) treatment was similar in VL+/– (placebo, 15.6%; rhAPC,12.1%) and VL–/– patients (placebo, 31.0%; rhAPC, 24.7%; interaction P = .981). VL+/– status did not appear to influence baseline biomarkers of coagulopathy and inflammation or disease severity, with the exception that vasopressor usage was less in VL+/– patients (46.2% versus 63.0%; P = .009). In a median lethal dose (40 mg/kg) endotoxin mouse model, VL+/– mice had lower mortality than wild-type mice (19% versus 57%; P = .008), whereas the mortality of homozygous (VL+/+) mice was almost identical to that of wild-type mice (65% versus 57%; P = .76). The findings suggest that FV Leiden constitutes a rare example of a balanced gene polymorphism that maintains the FV Leiden mutation in the general gene pool due to a survival advantage of VL+/– in severe sepsis.

1 September 2001 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
HWHartmut Weiler
Hartmut Weiler
VLVolkhard Lindner
Volkhard Lindner
BKBryce Kerlin
Bryce Kerlin
BIBerend H. Isermann
Berend H. Isermann
SHSara B. Hendrickson
Sara B. Hendrickson
JWJeffrey I. Weitz
Jeffrey I. Weitz
Mutations in the gene encoding thrombomodulin (TM), a thrombin regulator, are suspected risk factors for venous and arterial thrombotic disease. We have previously described the generation of TM Pro/Pro mice carrying a TM gene mutation that disrupts the TM-dependent activation of protein C. Here, it is shown that inbred C57BL/6J TM Pro/Pro mice exhibit a hypercoagulable state and an increased susceptibility to thrombosis and sepsis. Platelet thrombus growth after FeCl 3 -induced acute endothelial injury was accelerated in mutant mice. Vascular stasis after permanent ligation of the carotid artery precipitated thrombosis in mutant but not in normal mice. Mutant mice showed increased mortality after exposure to high doses of endotoxin and demonstrated altered cytokine production in response to low-dose endotoxin. The severity of the hypercoagulable state and chronic microvascular thrombosis caused by the TM Pro mutation is profoundly influenced by mouse strain-specific genetic differences between C57BL/6 and 129SvPas mice. These data demonstrate that in mice, TM is a physiologically relevant regulator of platelet- and coagulation-driven large-vessel thrombosis and modifies the response to endotoxin-induced inflammation. The phenotypic penetrance of the TM Pro mutation is determined by as-yet-uncharacterized genetic modifiers of thrombosis other than TM.

1 July 2009 in The Journal of Pediatrics
Verified
Journal Article
Closed access
BKBryce A. Kerlin
Bryce A. Kerlin
NBNeal B. Blatt
Neal B. Blatt
BFBeng Fuh
Beng Fuh
SZShuang Zhao
Shuang Zhao
ALAmy Lehman
Amy Lehman
WSWilliam E. Smoyer
William E. Smoyer